Oral etoposide as a single agent in childhood and young adult cancer in England: Still a poorly evaluated palliative treatment
Cameron, A. L.
Feltbower, R. G.
McCabe, Martin G
AffiliationNational Cancer Registration and Analysis Service (NCRAS), Public Health England, London
MetadataShow full item record
AbstractBackground: Oral etoposide is commonly used in palliative treatment of childhood and young adult cancer without robust evidence. We describe a national, unselected cohort of young people in England treated with oral etoposide using routinely collected, population-level data. Methods: Patients aged under 25 years at cancer diagnosis (1995-2017) with a treatment record of single-agent oral etoposide in the Systemic AntiCancer Dataset (SACT, 2012-2018) were identified, linked to national cancer registry data using NHS number and followed to 5 January 2019. Overall survival (OS) was estimated for all tumours combined and by tumour group. A Cox model was applied accounting for age, sex, tumour type, prior and subsequent chemotherapy. Results: Total 115 patients were identified during the study period. Mean age was 11.8 years at cancer diagnosis and 15.5 years at treatment with oral etoposide. Median OS was 5.5 months from the start of etoposide; 13 patients survived beyond 2 years. Survival was shortest in patients with osteosarcoma (median survival 3.6 months) and longest in CNS embryonal tumours (15.5 months). Across the cohort, a median of one cycle (range one to nine) of etoposide was delivered. OS correlated significantly with tumour type and prior chemotherapy, but not with other variables. Conclusions: This report is the largest series to date of oral etoposide use in childhood and young adult cancer. Most patients treated in this real world setting died quickly. Despite decades of use, there are still no robust data demonstrating a clear benefit of oral etoposide for survival.
CitationFraser J, Fardus‐Reid F, Irvine L, Elliss‐Brookes L, Fern L, Cameron AL, et al. Oral etoposide as a single agent in childhood and young adult cancer in England: Still a poorly evaluated palliative treatment. Pediatr Blood Cancer. 2021 Jul 6.
JournalPediatric Blood and Cancer
- Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma.
- Authors: Perret A, Dômont J, Chamseddine AN, Dumont SN, Verret B, Briand S, Court C, Lazure T, Adam J, Ngo C, Even C, Levy A, Bayle A, Lucibello F, Haddag-Miliani L, Faron M, Honoré C, Le Cesne A, Mir O
- Issue date: 2021 Jan
- Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma.
- Authors: Akazawa R, Umeda K, Saida S, Kato I, Hiramatsu H, Sakamoto A, Arakawa Y, Sumiyoshi S, Okamoto T, Moritake H, Adachi S, Takita J
- Issue date: 2020 Aug 4
- Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
- Authors: Gaspar N, Venkatramani R, Hecker-Nolting S, Melcon SG, Locatelli F, Bautista F, Longhi A, Lervat C, Entz-Werle N, Casanova M, Aerts I, Strauss SJ, Thebaud E, Morland B, Nieto AC, Marec-Berard P, Gambart M, Rossig C, Okpara CE, He C, Dutta L, Campbell-Hewson Q
- Issue date: 2021 Sep
- Bleomycin, etoposide and cisplatinum (BEP) chemotherapy for metastatic germ cell tumours: treatment outcomes at UKM medical centre, Malaysia.
- Authors: Azrif M, Leong YK, Aslan NM, Fong KV, Ismail F
- Issue date: 2012